Estimated by FDG PET/CT in Myocardial Sarcoidosis
Phase 3
- Conditions
- Cardiac sarcoidosis
- Registration Number
- JPRN-jRCTs041180111
- Lead Sponsor
- Murohara Toyoaki
- Brief Summary
After 6 months of prednisone treatment for cardiac sarcoidosis, 80.4% of patients had a reduction in the extent of abnormal FDG accumulation, and when the poor-responder group was re-treated with methotrexate or re-prednisone, there was no significant difference in the treatment effect between two groups.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 62
Inclusion Criteria
Cardiac sarcoidosis
Exclusion Criteria
1, Bone marrow suppression
2, Chronic hepatic disease
3, Chronic kidney disease
4, Insulin using
5, Active infection
6, Unsuitable patient
7, Under 20 years of age
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Decreasing rate of TLG by PSL therapy for 12 (18) months
- Secondary Outcome Measures
Name Time Method 1, Systolic and/or diastolic function <br>2, Respiratory function <br>3, Exercise function<br>4, Prognosis